The Neuromod Prize, a $9.8 million competition to accelerate the development of targeted neuromodulation therapies, has announced two Phase 3 winners. The competition aimed to advance neuromodulation solutions and brought them much closer to having tangible patient impact, offering new hope to the millions of patients battling chronic or acute diseases.
The prize did not just emphasize cutting-edge science, but also practicality — challenging teams to think beyond the lab, and to design solutions that could make their way into clinical use. This bold competition wanted innovation as well as translation, getting therapies into the hands of patients who need them. The Phase 3 teams demonstrated not only scientific brilliance but also the determination and creativity needed to advance neuromodulation therapies toward real-world impact.
On October 20, the Neuromod Prize announced the Phase 3 winners during a finalist showcase at HLTH 2025. Phase 3 teams presented their solutions to an audience of health tech leaders, innovators, and investors.